SCHEMBL4593022

SCHEMBL4593022

CC(C)C(C(N)=O)C(=O)Nc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
ALDH1A1 P00352 4/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
RXFP1 Q9HBX9 1/20 0.54
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA9 Q16790 2/20 0.54
TAAR1 Q96RJ0 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
POLB P06746 2/20 0.50
GAA P10253 2/20 0.50
LMNA P02545 1/20 0.50
ATM Q13315 1/20 0.50
TP53 P04637 1/20 0.49
MME P08473 1/20 0.47
ACE P12821 1/20 0.47
HPGD P15428 2/20 0.47
HTT P42858 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14853301 0.89 ALDH1A1 (0.61) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL10647387 0.84 MAPT (0.61) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL307289 0.81 MAPT (0.58) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL24832296 0.78 TAAR1 (0.59) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL836046 0.78 TAAR1 (0.59) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL835887 0.78 TAAR1 (0.59) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL4741417 0.77 TAAR1 (0.79) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL10787070 0.77 POLB (0.57) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL5960486 0.77 TAAR1 (0.79) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL12251076 0.77 ALDH1A1 (0.61) MAPTALDH1A1MEN1KMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957498-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING MethylGene Inc. (CA) 2008-08-20 EP claimed
WO-2008041053-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE, INC. (CA) 2008-04-10 WO claimed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US claimed
EP-1957498-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING MethylGene Inc. (CA) 2008-08-20 EP disclosed
WO-2008041053-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE, INC. (CA) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 MAPT 2430/4885ALDH1A1 1649/4885MEN1 3655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.